Literature DB >> 16822379

Emerging therapeutic options for atopic dermatitis: beyond TIMs.

Edward R Conner, Lisa A Beck.   

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts both patients and their families. Although current therapies provide relief of symptoms for most but not all patients, they do not prevent or eradicate the disease. In this new era of biological therapy, medications that precisely target the molecular mediators of inflammation are being developed at a rapid pace. These biologic agents have proven useful for treating many inflammatory illnesses, as well as providing insight into disease pathogenesis. In atopic dermatitis, these new therapies may prove highly useful to both treat and prevent the disease. In this review article, we briefly review the pathogenesis of AD to discuss current therapies and to introduce potential new treatments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822379     DOI: 10.1007/s11882-006-0060-1

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  51 in total

1.  Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial.

Authors:  K Wolff; C Fleming; J Hanifin; K Papp; S Reitamo; M Rustin; N Shear; W Silny; N Korman; I Marks; R Cherill; S Emady-Azar; C Paul
Journal:  Br J Dermatol       Date:  2005-06       Impact factor: 9.302

Review 2.  Therapeutic options in the treatment of psoriasis and atopic dermatitis.

Authors:  Alice B Gottlieb
Journal:  J Am Acad Dermatol       Date:  2005-07       Impact factor: 11.527

3.  The structure of normal skin and the morphology of atopic eczema.

Authors:  M C Mihm; N A Soter; H F Dvorak; K F Austen
Journal:  J Invest Dermatol       Date:  1976-09       Impact factor: 8.551

Review 4.  Methotrexate in psoriasis: consensus conference.

Authors:  H H Roenigk; R Auerbach; H Maibach; G Weinstein; M Lebwohl
Journal:  J Am Acad Dermatol       Date:  1998-03       Impact factor: 11.527

5.  Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months.

Authors:  S F Friedlander; A A Hebert; D B Allen
Journal:  J Am Acad Dermatol       Date:  2002-03       Impact factor: 11.527

6.  Expression of endothelial-leukocyte adhesion molecule-1 in elicited late phase allergic reactions.

Authors:  D Y Leung; J S Pober; R S Cotran
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

7.  Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial.

Authors:  J Berth-Jones; A Takwale; E Tan; G Barclay; S Agarwal; I Ahmed; K Hotchkiss; R A C Graham-Brown
Journal:  Br J Dermatol       Date:  2002-08       Impact factor: 9.302

8.  Evidence of a role of tumor necrosis factor alpha in refractory asthma.

Authors:  Mike A Berry; Beverley Hargadon; Maria Shelley; Debbie Parker; Dominick E Shaw; Ruth H Green; Peter Bradding; Christopher E Brightling; Andrew J Wardlaw; Ian D Pavord
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

Review 9.  Cost of illness of atopic dermatitis in children: a societal perspective.

Authors:  Andrew S Kemp
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  Experience with low-dose methotrexate for the treatment of eczema in the elderly.

Authors:  Freida C G Shaffrali; Graham B Colver; Andrew G Messenger; David J Gawkrodger
Journal:  J Am Acad Dermatol       Date:  2003-03       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.